Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BBLG 
Bone Biologics Corp (BBLG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BBLG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.33% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.77M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 1 | Beta 1.19 | 52 Weeks Range 2.17 - 16.50 | Updated Date 08/15/2025 |
52 Weeks Range 2.17 - 16.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -23.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.73% | Return on Equity (TTM) -129.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1025806 | Price to Sales(TTM) - |
Enterprise Value 1025806 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.13 | Shares Outstanding 1605260 | Shares Floating 492096 |
Shares Outstanding 1605260 | Shares Floating 492096 | ||
Percent Insiders 9.29 | Percent Institutions 0.13 |
Upturn AI SWOT
Bone Biologics Corp
Company Overview
History and Background
Bone Biologics Corp (BBLG) is a biotechnology company focused on bone regeneration. Founded to develop and commercialize osteopromotive protein therapies for spinal fusion, fracture healing and other orthopedic conditions. Milestones include preclinical studies and clinical trials of their NB-101 bone graft substitute.
Core Business Areas
- Bone Regeneration Therapies: Development of NB-101, a recombinant human protein used as a bone graft substitute for spinal fusion procedures and fracture healing.
- Licensing and Commercialization: Seeking partnerships for licensing and commercialization of their products in various markets.
Leadership and Structure
Details on leadership are limited in publicly available sources, typically a CEO and a Board of Directors. Public companies must also adhere to federal regulations.
Top Products and Market Share
Key Offerings
- NB-101: NB-101 is Bone Biologics Corp's lead product, a bone graft substitute for spinal fusion procedures. Market share data is currently unavailable due to it being in clinical trials, awaiting regulatory approvals to commercialize. Competitors include Medtronic (MDT), Stryker (SYK), and Zimmer Biomet (ZBH) which all make Bone Grafts and biologics.
Market Dynamics
Industry Overview
The bone graft substitute market is growing, driven by an aging population, increasing incidence of spinal disorders, and technological advancements in regenerative medicine.
Positioning
Bone Biologics aims to capture market share in the bone graft substitute market through its novel NB-101 protein. Competitive advantage hinges on proving superior efficacy and safety compared to existing bone graft options.
Total Addressable Market (TAM)
The global bone graft and substitutes market is estimated to reach multi-billions of dollars. Bone Biologics is aiming to enter this market, with its technology.
Upturn SWOT Analysis
Strengths
- Proprietary NB-101 technology
- Potential for improved bone regeneration
- Experienced scientific team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Lack of commercialized products
Opportunities
- Partnerships with larger orthopedic companies
- Expansion into new orthopedic indications
- Favorable regulatory environment
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MDT
- SYK
- ZBH
Competitive Landscape
Bone Biologics faces a challenging competitive landscape due to established companies with extensive resources. Their advantage depends on differentiating NB-101.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal, the company currently has no products generating revenue.
Future Projections: Future growth depends on the success of NB-101 and successful commercialization. Analyst estimates are highly speculative.
Recent Initiatives: Recent initiatives include continued clinical trials and seeking partnership opportunities.
Summary
Bone Biologics Corp is a high-risk, high-reward biotechnology company focusing on bone regeneration. It lacks current revenue, is experiencing losses and faces significant competition. The company's future hinges on the success of NB-101's clinical trials and their ability to secure partnerships. Investors must be aware of the speculative nature of the investment and the long development timelines common in the biotechnology sector.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2016-03-31 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.